Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 15/20 | 0.49 |
| ▸ | PI4KA | P42356 | 2/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30400679 | 0.84 | PI4KA (0.55) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10965960 | 0.84 | PI4KA (0.55) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14649524 | 0.84 | PI4KA (0.55) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9975356 | 0.81 | EGFR (0.42) | MAP4K4EGFRIRAK4 | |
| SCHEMBL25552038 | 0.78 | EGFR (0.40) | MAP4K4EGFRIRAK4 | |
| SCHEMBL13843541 | 0.78 | MAP4K4 (0.50) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17661303 | 0.78 | MAP4K4 (0.49) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL282157 | 0.78 | ENPP1 (0.44) | EGFRIRAK4 | |
| SCHEMBL17661304 | 0.77 | PDE5A (0.51) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28755513 | 0.77 | PI4KA (0.52) | MAP4K4PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | MAP4K4 4230/4885PI4KA 3221/4885PI4K2B 2874/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | MAP4K4 3359/4885PI4KA 3156/4885PI4K2B 2301/4885 |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | MAP4K4 3766/4885PI4KA 3568/4885PI4K2B 3045/4885 |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | MAP4K4 3845/4885PI4KA 3322/4885PI4K2B 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.